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Introduction
Inflammatory bowel disease (IBD), which affects 1 in 600 Americans, is characterized by severe and chronic inflammation. Such inflammation is a known contributor to cancer as it promotes an environment rich in chemokines, cytokines, and reactive oxygen species (ROS) influencing epithelial proliferation and survival programs and impacting genomic integrity (1, 2). For example, patients with IBD demonstrate increased nitric oxide production via activated macrophages and granulocytes and increased plasma levels of the marker for DNA damage 8-hydroxydeoxyguanosine (1, 3).
As such, the risk for cancer is increased 6-fold in patients with IBD compared with the general population, and cancer, or risk thereof, is a cause of significant morbidity in IBD (4).
Selenium is a necessary trace element that is present in the primary structure of selenoproteins as selenocysteine. Several epidemiological studies have inversely correlated nutritional selenium status with colon and prostate cancer risk, although this is somewhat controversial. The effect of selenium status in IBD has not been definitively evaluated. It is proposed that the effect of selenium on carcinogenesis is realized by the selenoproteins into which it is incorporated. In support of this, mouse models with impaired selenoprotein expression demonstrate increased aberrant crypt foci, a preneoplastic colon lesion, and breast cancer incidence (5, 6). The selenocysteine present in the catalytic triad of glutathione peroxidases is optimized by hydrogen bonding with glutamine and tryptophan residues, enhancing its activity and, in the case of certain glutathione peroxidases such as GPX1, this allows it to exert antioxidant activity (7, 8) .
One mechanism, though by no means the only, by which glutathione peroxidases may reduce cancer risk is by blunting the tumor-promoting effects of oxidative stress.
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Author Manuscript Published OnlineFirst on December 5, 2012; DOI: 10.1158/0008-5472.CAN-12-3150 Ͷ Gpx3, or plasma glutathione peroxidase, is the only known selenocysteinecontaining extracellular form of glutathione peroxidase (Gpx) and accounts for nearly all of the glutathione peroxidase activity in plasma (9). Gpx3 mRNA is expressed in a tissuespecific manner by the kidney, heart, lung, liver, brain, adipose tissue, breast, and gastrointestinal tract, but the majority of plasma Gpx3 is kidney-derived (10-12). It is likely that other organs contribute to plasma Gpx3 as nephrectomized rats retain 30% of original glutathione peroxidase activity (13). Gpx3 is transported via circulation where it binds to the basement membranes of epithelial cells such as those in the gastrointestinal tract (14). Gpx3 promoter hypermethylation and downregulation is commonly seen in human cancer (15) (16) (17) (18) . In prostate cancer, hemizygous and homozygous deletions as well as methylation of the first exon of Gpx3 frequently occur (17). Promoter hypermethylation insures decreased expression of Gpx3 in gastric, cervical, thyroid, head and neck, and lung cancers, and in melanoma (15, 16) suggesting that Gpx3 serves as a tumor suppressor in these cancers. Genetic evidence supports a role for GPX enzymes in IBD with Gpx1;Gpx2 double knockout mice developing spontaneous ileocolitis (19) and intestinal carcinoma that is associated with bacteria-induced inflammation (20) . In fact, Gpx2 alone may have a protective role in inflammatory carcinogenesis (21) . The role of Gpx3 in these processes has never been directly tested.
We hypothesized that loss of Gpx3 would enhance tumorigenesis in inflammatory carcinogenesis, a process rich in ROS production and chemokine/cytokine driven pro-proliferative stromal signals (1, 2, (22) (23) (24) 
Materials and Methods

Murine Inflammatory Carcinogenesis and Chronic Colitis Protocols: 7-8 week old
C57Bl/6 WT (n=17) or congenic Gpx3 -/-(n=20) mice were injected with 12.5 mg/kg of AOM (Sigma-Aldrich) intraperitoneally as described in Greten, et al (25) . After a threeday recovery period the animals were started on the first of four cycles of 3% DSS ad libitum (see Schematic in Figure 1A ). Each cycle lasted 5 days and was separated by a 16-day recovery period. A second DSS-only control arm was included for C57Bl/6 WT (n=14) and Gpx3 -/-(n=19) that followed the same protocol outlined above excluding the AOM injection. After the last cycle, animals were sacrificed following a 26-day recovery period. Tumor counts and measurements were performed in a blinded fashion under a stereo dissecting microscope. Each colon was then bisected longitudinally and half was Immunohistochemistry and immunofluorescence: Five-micrometer sections were cut, dewaxed, hydrated and endogenous peroxidase activity quenched with 0.03% hydrogen peroxide in MeOH. Antigen retrieval was performed using the boiling sodium citrate method in a microwave (20 mmol sodium citrate pH 6.5) for 16 minutes at 30% power. Polybrene (Millipore) was added to the filtered media. Growth medium was removed from Caco2 cells and replaced with infection medium. After 6 hours, the infection medium was replaced with normal growth medium and the infection process was repeated 24 hours later. Cells were selected for knockdown using 5 μg/ml Puromycin (Invitrogen) over a 3-day period. Knockdown was analyzed by the delta-delta-CT method following RT-PCR using Gpx3-specific Taqman probes (Invitrogen) and by Western blotting using rabbit anti-mouse Gpx3 8096 (dilution 1:5000; custom-made by Rockland).
ROS Determination:
Caco2 cells infected with either scrambled or Gpx3-specific shRNA were pre-treated with 500 U/ml PEGylated catalase (PEG-CAT, Sigma) one hour prior to 1.5 hour treatment with 200 μM H 2 O 2 . Either ROS detection reagent 6-carboxy-2',7'-dichlorodihydrofluorescein diacetate, di(acetoxymethyl ester) (DCFH2, Invitrogen) or the oxidation insensitive analog of DCFH2 (DCF, Invitrogen) was used to stain treated cells according to the manufacturer's protocol for flow cytometry analysis. In short, cells plated on a 6-well plate in phenol red-free medium were washed with 500 ȝl PBS. Cells were then resuspended in 1 ȝM DCFH2 or 0.5 ȝM DCF in pre-warmed PBS and incubated for either 20 minutes or 5 minutes at 37°C, respectively. Cells were then washed twice with PBS and centrifuged at 1600 rpm for 6 minutes between washes. Cells 
Matrigel Colony Formation Assay:
The day prior to Matrigel plating, Matrigel (BD, 354234) at 9 mg/ml was thawed overnight in ice at 4°C. For each well of a 48-well plate, 50 ȝl ice cold Caco2 media (DMEM supplemented with 10% FBS and pen/strep) was mixed with 50 ȝl Matrigel.
Plates were then allowed to solidify at 37°C for thirty minutes. Caco2 cells were trypsinized, washed with PBS, and diluted to 10,000 cells/ml in 2 ml media. A 1:1 mixture of cells and Matrigel was added to the wells in the prepared 48-well plate and incubated at 37°C for thirty minutes. To avoid drying, 200 ȝl complete Caco2 media was added to each Matrigel-filled well. Cells were maintained at their normal growth conditions and media was changed every 2-3 days. On day 22, cells were counted using GelCount (Oxford Optronix, Oxford, UK). 
Results
Glutathione peroxidase activity is decreased and oxidative stress is increased in AOM/DSS-treated mice. Gpx3 is often downregulated in cancer (15-18) and we sought to determine whether its expression or activity was altered in the AOM/DSS model of inflammatory carcinogenesis. For these experiments, 7-8 week old mice were injected with AOM and treated with 4 cycles of DSS as defined in the Methods section and shown in Figure 1A . During the course of this protocol, six Gpx3 -/-mice died (lost over 20% of original body weight and were sacrificed), two after cycle 1, two after cycle 2, and two during cycle 4 of DSS. Whereas, as is typical with this protocol, two WT mice died, both after cycle 4, a time when we usually see mortality. These mice were not included in the final analysis. This increased morbidity suggests that Gpx3 may protect the mucosa from DSS induced injury.
As decreased Gpx3 levels are commonly seen in cancer, we first tested plasma Gpx3 activity in mice receiving water only versus mice post the AOM/DSS protocol to determine if Gpx3 activity might be altered. Measurement of oxidation of NADPH allowed us to determine that AOM/DSS leads to diminished plasma glutathione peroxidase activity (497.7 ± 56.9 versus 239.4 ± 40.8 nmol NADPH oxidized/ml plasma/min, P=0.0013, Fig. 1B ). As this indicated that there was a systemic decrease in glutathione peroxidase activity and protein levels of Gpx3 in the plasma validated glutathione peroxidase activity assays (Fig. S1 ), we next wanted to determine if local Gpx3 mRNA levels were affected in AOM/DSS tumorigenesis. There was no difference in Gpx3 mRNA expression between matched tumor and adjacent normal mucosa samples (Fig. S2 ), but other oxidative stress response genes were upregulated in normal adjacent (Fig. 1C) suggesting an increase in oxidant stress resulting from the protocol. Finally, we wanted to determine if GPX3 expression varied in a large colorectal cancer expression array dataset, and in this case GPX3 was markedly and consistently underexpressed as early as the adenoma stage (Fig. S3A) . We confirmed this observation with 10 matched normal/colon cancer samples by qRT-PCR, and in a second set of 10 matched samples by protein analysis, finding reduced GPX3 levels in 80% of the samples (Fig. S3B & C) . These results support previous studies (18) and suggest that GPX3 may serve as a tumor suppressor in colorectal cancer.
Gpx3 is a tumor suppressor in inflammatory tumorigenesis. Utilizing the Gpx3
-/-mouse, we directly tested whether Gpx3 was a tumor suppressor in the AOM/DSS model. 7-8 week old WT or Gpx3 -/-mice were placed on the AOM/DSS protocol (Fig. 1A) . As expected, mice lost weight and had looser stools as the result of DSS administration in both the DSS and AOM/DSS arms of the experiment (Fig. S4) , though there was no significant difference between genotypes in these parameters. Gpx3 protein is normally seen in the colon binding the basement membrane on the basolateral surface (14) ( (Fig. S5) . ROS is produced during the AOM/DSS protocol as evidenced by increased expression of oxidative stress response genes ( Fig. 1C and (40) Fig. 5C ).
GPX3 knockdown in vitro leads to increased ROS levels and DNA damage. To determine whether knockdown of GPX3 in vitro would recapitulate results seen in vivo
we used shRNA to GPX3 in the human colon cancer cell line Caco2. Caco2 cells were used as a model cell line because they express high levels of endogenous GPX3 compared to other colon cancer cell lines ( Fig. S6A & B) . shRNA-mediated knockdown resulted in decreased GPX3 expression both at the mRNA and protein levels (Fig. 6A ).
At baseline, knockdown of GPX3 had no impact on ROS production or DNA damage, though stimulation with hydrogen peroxide (H 2 O 2 ) resulted in a significant increase in ROS (16.1% versus 7.3%, P=0.0019), which was abolished with pre-treatment with the H 2 O 2 scavenger PEG-CAT. Furthermore, GPX3 knockdown had no effect on the activity of the oxidation-insensitive DCFH2 + analog, DCF + ( Figure 
Discussion
Chronic inflammation, as seen in ulcerative colitis and Crohn's colitis, predisposes to malignancy (2). In fact, the risk for cancer is increased 6-fold in patients with IBD compared with the general population (4). Although the relationship between chronic inflammation and carcinogenesis is complicated and imprecisely understood, it is hypothesized that the excess ROS and reactive nitrogen species (RNS) accompanying inflammation contribute to malignancy. During chronic inflammation superoxide is produced at rates that overwhelm antioxidant systems (42, 43) . When reactive oxygen and nitrogen species are not cleared efficiently, they begin to react with lipids, proteins, and DNA (44). More specifically, oxidative DNA damage leads to C/G base pair mutations which lead to an increased frequency of C:GAET:A transversion (45), a mutation which is most frequently observed in mutated proto-oncogenes and tumor suppressor genes (46). GPX3 is an extracellular glutathione peroxidase that is able to abrogate ROS and is postulated to protect from carcinogenesis via these activities, although this has up to now not been rigorously tested using reverse genetics. We applied this approach to define the role of Gpx3 in inflammatory carcinogenesis and now demonstrate that Gpx3 is indeed a potent inhibitor of tumor promotion and progression. CAN-12-3150 ͳͻ Thus, our data suggest that at least part of the immune cell modifying properties of selenium are actuated by Gpx3.
Thus far, our data supports a tumor suppressor role for Gpx3 via clearance of ROS. Upon knockdown of Gpx3 in the human colorectal cancer cell line Caco2, we saw an induction of ROS as well as an increase in DNA damage resulting from hydrogen peroxide treatment that supports our in vivo data. Contrary to what was originally expected, knockdown of Gpx3 did not alter proliferation at baseline or during stress as was seen in vivo. Instead, apoptosis was increased in response to H 2 O 2 administration, a result that would be expected in cells that do not harbor the capacity to deal with oxidative stress due to the loss of the antioxidant Gpx3. Even at baseline, knockdown of Gpx3 in Caco2 cells resulted in a decrease in contact-independent cell growth, a marker of tumorigenicity. This is contrary to our in vivo findings in which Gpx3 served as a tumor suppressor. Though initially surprising, we hypothesize that the tumor suppressive role of Gpx3 exists in its ability to prevent the initiation and malignant transformation in vivo, but in cells that are already malignant, Gpx3 is able to promote tumorigenesis by protecting them from apoptosis. This also likely explains why, despite having higher proliferation rates, the tumors of Gpx3 -/-mice are not larger than those of WT mice. It may be that, upon the application of a stressor such as DSS, malignant cells in Gpx3 -/-mice are dying more rapidly than those in WT mice and stabilizing the tumor size.
In conclusion, we demonstrate that removal of Gpx3 enhances inflammation and injury, proliferation, nuclear β-catenin, and DNA damage in tumors of mice subjected to an inflammatory carcinogenesis protocol. The net effect of these changes leads to an increase in tumor promotion in response to Gpx3 loss. Thus, Gpx3 appears to serve as a December 5, 2012; DOI: 10.1158/0008-5472.CAN-12-3150 ʹͲ tumor suppressor in CAC. These studies provide insight into disease pathogenesis and indicate that at least one of the selenoproteins that modifies carcinogenesis is Gpx3 and that it may serve as a substrate for translational investigations in colitis-associated carcinoma.
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